# US 2016/0256473 A1 · Oromucosal Liquid Estradiol Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256473 A1
- Document ID: US20160256473A1
- Status: Published application
- Kind: A1
- Application number: 15/155,410
- Filed: 2016-05-16
- Published: 2016-09-08
- Earliest claimed: 2012-01-04
- Assignees: Innotesto Bvba
- Applicants: Innotesto Bvba
- Inventors: Franciscus Wilhelmus Henricus Maria Merkus
- Web page: https://patentgrep.com/patent/US20160256473A1

## CPC

- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 5/30: Oestrogens
- A61P 15/12: for climacteric disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to low dose estradiol solutions for oromucosal administration suitable in replacement therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with low endogenous levels of estradiol in female subjects.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of treating a human female patient having reduced estradiol levels, said method comprising administering oromucosally to a human female patient in need thereof one or more doses of a solution comprising 0.01-0.9% (w/v) of estradiol, or an equivalent amount of a pharmaceutically acceptable hydrate or ester thereof, 5-30% (v/v) of ethanol and 70-95% (v/v) of an ester of a C2-6 alcohol and a C8-22 fatty acid; wherein said dose comprises 0.01-0.3 mg of estradiol, or an equivalent amount of a pharmaceutically acceptable hydrate or ester thereof, wherein the solution is administered 1-6 times per day by spray, by drops or by a dosage pen, and wherein the solution does not contain water.

### Claim 22 (depends on 21)

The method according to claim 21, wherein a volume between about 10-500 μl of the estradiol solution is administered per dose.

### Claim 23 (depends on 21)

The method according to claim 21, wherein said dose is administered intermittently in a time period in the range 1 to 4 hours.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the elevation and control of the estradiol levels in the female patient results in treating, preventing or relieving symptoms caused by insufficient endogenous production of estrogen, such as headaches, nausea, vasomotor symptoms (hot flushes), symptoms of urogenital atrophy, decrease in bone mineral density, osteoporosis and increased risk or incidence of bone fractures.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the solution comprises 10-30% (v/v) of ethanol and 70-90% (v/v) of said ester.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the C2-6 alcohol is selected from ethanol, 1-propanol, isopropanol, butanol, pentanol, hexanol, propylene glycol, and glycerol; and the C8-22 fatty acid is selected from myristic acid, palmitic acid, stearic acid, arachidic acid and oleic acid.

### Claim 27 (depends on 21)

The method according to claim 21, wherein the ester of the C8-22 fatty acid and C2-6 alcohol is isopropyl myristate, isopropyl palmitate or isopropyl stearate.

### Claim 28 (depends on 21)

The method according to claim 21, wherein the ester of the C8-22 fatty acid and C2-6 alcohol is a vegetable oil, such as sesame oil, corn oil, castor oil or olive oil.

### Claim 29 (depends on 21)

The method according to claim 21, comprising 0.01-0.9% of estradiol (w/v), 10 -30% (v/v) ethanol (v/v) and 70-90% (v/v) isopropyl myristate.

### Claim 30 (depends on 21)

The method according to claim 21, wherein the ratio of the volumes of said ethanol to said ester of a C2-6 alcohol and a C8-22 fatty acid is 30:70, 25:75, 20:80, 15:85, or 10-90 (v/v%).
